|Stage of funding:||Current|
|Therapeutic group:||Inflammatory Diseases|
Celtaxsys is a clinical-stage development company focused on novel therapeutics that treat inflammatory disease through regulation of immune cell migration and activation. The company is building a sustainable pipeline of first-in-class immuno-modulators.
The lead drug candidate, acebilustat is a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor – the key enzyme in the production of the powerful promoter of inflammation Leukotriene B4 (LTB4). Both LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in Cystic Fibrosis (CF). Acebilustat has been shown to be effective in several CF-related, pre-clinical and clinical models and has been well tolerated in healthy volunteers and CF patients.
Celtaxsys is located in Atlanta, GA with a subsidiary office in Brisbane, Queensland, Australia.
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees. The study is being conducted with the Uniformed Services University of the Health Sciences (USU) and is enrolling U.S. Army Infantry trainees at Fort Benning, GA. NDV-3A is the company’s lead development candidate to potentially treat antimicrobial resistant fungal and bacterial pathogens.
12 April 2018
30 March 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
14 March 2018